Indian exports to suffer on FDA crackdown; Shkreli fires his defense lawyers; Alexion moves into New Haven HQ;

@FiercePharma: Roche blindsided by off-label Avastin fallout in India. More | Follow @FiercePharma

@CarlyHFierce: ICYMI: Big question for Pfizer: Will Enbrel's EU biosim bring on the pain? Story | Follow @CarlyHFierce

> An FDA crackdown in India and stepped-up competition in the industry could halve the country's growth in pharma exports over the next four years, a new report said. Report

> Pharma bad boy Martin Shkreli, who touched off a drug-pricing firestorm when he was CEO of Turing Pharmaceuticals, is looking for new lawyers to help him fight securities fraud allegations. Report

> Alexion Pharmaceuticals ($ALXN) moved 200 employees into its new headquarters in New Haven, CT, bringing customers to downtown-area businesses. Report

> UCB has won European approval for epilepsy drug Briviact. Report

> The diabetes boom in China represents a $23 billion opportunity for drugmakers such as Novo Nordisk ($NVO), Sanofi ($SNY) and Eli Lilly ($LLY). Report

Medical Device News

@FierceMedDev: IBM bets its future on machine learning and Watson Health. More | Follow @FierceMedDev

@VarunSaxena2: Interesting article in @TheEconomist. Which lifesci hub do you think is no. 1? Poll | Follow @VarunSaxena2

@EmilyWFierce: Roche blindsided by off-label Avastin fallout in #India. Story | Follow @EmilyWFierce

> Spanish researchers prototype robotic arm for shoulder rehabilitation. More

> Randomized trial finds smartphone-enabled patient monitors don't decrease healthcare utilization. Article

Biotech News

@FierceBiotech: Top 10 mega-rounds fuel record VC pace, with a distinctly ex-U.S. biotech accent. Report | Follow @FierceBiotech

@JohnCFierce: Seeing some silly reactions to $ZFGN this a.m. No trial that ends in a complete hold is a "success," and efficacy data won't lift that hold. | Follow @JohnCFierce

@DamianFierce: Index Ventures' official Dick Costolo announcement is a link to his tweets of screenshots from his notes app. Website | Follow @DamianFierce

> Bristol-Myers moves forward with its $1.2B CytomX alliance. Item

> Surrounded by top scientists, Biden hustles up support for accelerated cancer R&D. Article

Biotech Research News

> New study offers researchers a guide to making next-gen TB drugs. More

> Allergan highlights preclinical evidence of cognitive safety for fast-acting depression drug. News

> Scripps team spots a new mechanism that drives Celgene's ozanimod, potential rivals. Story

> Columbia U. team refines replacement cells for injured hearts. Article

> Study presents a fresh opportunity for early ovarian cancer diagnosis. Report

Pharma Marketing News

> Glass half empty? Pharma staffers about as content as average Americans, survey finds. Story

> Pharma's December TV spending sags; Pfizer and BMS' Eliquis rises to top. News

> Takeda's U.K. unit brings sales force in-house to boost efforts in oncology, IBD. Report

> Merck & Co. sues Merck KGaA over naming rights in transatlantic tug-of-war. Article

> Minds + Assembly jumps off big pharma agencies, aims for 'breakthrough' work with Orexo. More

Vaccines News

> Merck to submit Ebola vaccine for regulatory approval in 2017. Story

> FDA expands indication for GSK's Hib vaccine, Hiberix. News

> Dengue vaccine developed at NIH enters PhIII in Brazil. More

> Baltimore's Profectus BioSciences starts PhI trial of Ebola vaccine. Report

> Sanofi working with health authorities on dengue vaccine strategies. Article

And Finally... Vice President Joe Biden pledged to speed up approval of combination cancer therapies, partly by encouraging different drugmakers to test their pipeline products together. Report.

Suggested Articles

Mylan and Pfizer's Upjohn have a name for their pending merger: Viatris. Heard that before? So has Mylan, which owns a subsidiary with the same name.

Intercept presented a data analysis that found treatment with Ocaliva led to "early and consistent improvements" in a range of noninvasive tests.

Days before Amarin faces a pivotal FDA vote on its Vascepa expansion, advisors are set to scrutinize the placebo used in its pivotal outcomes trial.